Language:

Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset

Ophthalmology (Rochester, Minn.), 2021-05, Vol.128 (5), p.649-660 [Peer Reviewed Journal]

Copyright © 2020 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0161-6420 ;EISSN: 1549-4713 ;DOI: 10.1016/j.ophtha.2020.12.012 ;PMID: 33451738

Digital Resources/Online E-Resources

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset
Author: Newman, Nancy J ; Yu-Wai-Man, Patrick ; Carelli, Valerio ; Moster, Mark L ; Biousse, Valerie ; Vignal-Clermont, Catherine ; Sergott, Robert C ; Klopstock, Thomas ; Sadun, Alfredo A ; Barboni, Piero ; DeBusk, Adam A ; Girmens, Jean François ; Rudolph, Günther ; Karanjia, Rustum ; Taiel, Magali ; Blouin, Laure ; Smits, Gerard ; Katz, Barrett ; Sahel, José-Alain
Subjects: Adolescent ; Adult ; Aged ; Dependovirus - genetics ; DNA, Mitochondrial - genetics ; Double-Blind Method ; Electroretinography ; Female ; Follow-Up Studies ; Genetic Therapy ; Genetic Vectors ; Humans ; Intravitreal Injections ; Life Sciences ; Male ; Middle Aged ; Mutation ; Optic Atrophy, Hereditary, Leber - diagnosis ; Optic Atrophy, Hereditary, Leber - genetics ; Optic Atrophy, Hereditary, Leber - psychology ; Optic Atrophy, Hereditary, Leber - therapy ; Quality of Life - psychology ; Time Factors ; Treatment Outcome ; Visual Acuity - physiology ; Visual Field Tests ; Visual Fields - physiology ; Young Adult
Is Part Of: Ophthalmology (Rochester, Minn.), 2021-05, Vol.128 (5), p.649-660
Description: To evaluate the efficacy of a single intravitreal injection of rAAV2/2-ND4 in subjects with visual loss from Leber hereditary optic neuropathy (LHON). RESCUE is a multicenter, randomized, double-masked, sham-controlled, phase 3 clinical trial. Subjects with the m.11778G>A mitochondrial DNA mutation and vision loss ≤6 months from onset in 1 or both eyes were included. Each subject's right eye was randomly assigned (1:1) to treatment with rAAV2/2-ND4 (single injection of 9 × 10 viral genomes in 90 μl) or to sham injection. The left eye received the treatment not allocated to the right eye. The primary end point was the difference of the change from baseline in best-corrected visual acuity (BCVA) between rAAV2/2-ND4-treated and sham-treated eyes at week 48. Other outcome measures included contrast sensitivity, Humphrey visual field perimetry, retinal anatomic measures, and quality of life. Follow-up extended to week 96. Efficacy analysis included 38 subjects. Mean age was 36.8 years, and 82% were male. Mean duration of vision loss at time of treatment was 3.6 months and 3.9 months in the rAAV2/2-ND4-treated eyes and sham-treated eyes, respectively. Mean baseline logarithm of the minimum angle of resolution (logMAR) BCVA (standard deviation) was 1.31 (0.52) in rAAV2/2-ND4-treated eyes and 1.26 (0.62) in sham-treated eyes, with a range from -0.20 to 2.51. At week 48, the difference of the change in BCVA from baseline between rAAV2/2-ND4-treated and sham-treated eyes was -0.01 logMAR (P = 0.89); the primary end point of a -0.3 logMAR (15-letter) difference was not met. The mean BCVA for both groups deteriorated over the initial weeks, reaching the worst levels at week 24, followed by a plateau phase until week 48, and then an improvement of +10 and +9 Early Treatment Diabetic Retinopathy Study letters equivalent from the plateau level in the rAAV2/2-ND4-treated and sham-treated eyes, respectively. At 96 weeks after unilateral injection of rAAV2/2-ND4, LHON subjects carrying the m.11778G>A mutation treated within 6 months after vision loss achieved comparable visual outcomes in the injected and uninjected eyes.
Publisher: United States: Elsevier
Language: English
Identifier: ISSN: 0161-6420
EISSN: 1549-4713
DOI: 10.1016/j.ophtha.2020.12.012
PMID: 33451738
Source: Hyper Article en Ligne (HAL) (Open Access)

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset

Copyright © 2020 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0161-6420 ;EISSN: 1549-4713 ;DOI: 10.1016/j.ophtha.2020.12.012 ;PMID: 33451738

Searching Remote Databases, Please Wait